Research
Hormonal
Postmenopausal hormone therapy (estrogen alone or combined with progestin) is not associated with a significant decrease in the risk of stroke, and may be associated with an increased risk of ischemic stroke.
For postmenopausal women, hormone therapy (estrogen alone or combined) does not reduce the risk of stroke. There is a suggestion of an increased risk of ischemic stroke among users, particularly with higher doses of estrogen.
GoodRefutesHIGH confidence
However, there was no significant association between stroke and use of combined hormones (multivariate adjusted relative risk, 1.09; 95 percent confidence interval, 0.66 to 1.80) or estrogen alone (relative risk, 1.27; 95 percent confidence interval, 0.95 to 1.69).
Why this rating
Same large prospective cohort study with long follow-up and multivariate adjustment.
Source
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Francine Grodstein et al. · New England Journal of Medicine · 1996
DOI 10.1056/nejm199608153350701
cohort · n=59337Cited 1,321×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →